MACE-ICH trial — DEMO SITE
MAnnitol for Cerebral oEdema after IntraCerebral Haemorrhage


EudraCT 2022-000283-22
Twitter
Room S/D2105, Stroke Trials Unit
School of Medicine, University of Nottingham
Queen's Medical Centre, Derby Road
Nottingham NG7 2UH, United Kingdom
The recruitment total for the trial to date is: 13

Login using the investigator ID, password issued to you by the

If you have forgotten your login details then please click here.

MACE-ICH is now closed to recruitment.
Please continue to enter follow-up data and SAEs for existing participants.

MACE-ICH investigator ID:
Password:

Please ensure that your web browser has both cookies and JavaScript enabled.

  • Serious Adverse Events (SAEs) — we have a legal responsibility to collect all SAEs occurring within the first 28 days after randomisation (including SARs/SUSARs/fatal SAEs).
  • Please remember that fatal SAEs and safety outcome events – thrombophlebitis, hyper-/hyponatraemia, pulmonary oedema, hypotension and renal impairment – need to be reported until the final month 6 follow-up, even if this is after 28 days.
  • Please assess if expected according to RSI: https://medicines.org.uk/emc/product/1839/smpc
    Expectedness should only be assessed in events that are thought to be possibly/probably/definitely related to the IMP.
  • Investigators have a legal responsibility to report applicable SAEs to the sponsor without delay, within 24 hours.

Latest recruiting hospitals
Nottingham TEST hospital, NOTTINGHAM, UK
Derby TEST hospital, DERBY, UK